BioVie Inc.
BIVI · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | -0.06 | 0.01 |
| FCF Yield | -139.22% | -152.59% | -28.75% | -53.24% |
| EV / EBITDA | 0.21 | -0.02 | -3.01 | -1.09 |
| Quality | ||||
| ROIC | -93.31% | -148.86% | -151.48% | -170.08% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.08 | 0.87 | 0.80 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 31.92% | 30.58% | -111.96% | -81.68% |
| Safety | ||||
| Net Debt / EBITDA | 1.01 | 0.56 | 0.11 | 0.24 |
| Interest Coverage | -54.30 | -11.12 | -10.48 | -12.60 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -0.00 | 0.00 | 0.00 | 0.00 |